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ABSTRACT
Aim: To determine in vivo whether the lateral geniculate
nucleus (LGN) undergoes atrophy in patients with
glaucoma and vision loss compared with normal subjects.
Methods: Following institutional St Michael’s Hospital
Research Ethics Board approval, a prospective and
masked neuroimaging study was conducted on glaucoma
patients with visual-field defects affecting both eyes
(n=10) and age-matched controls (n=8). Following
informed consent, all subjects underwent 1.5-Tesla MRI.
Coronal proton density magnetic resonance images of
both LGNs were obtained, and LGN height measurements
were measured by consensus by three neuroradiologists
masked to the diagnosis. Glaucoma and control groups
were compared using the t test.
Results: Both LGNs were identified and visualised by 1.5-
Tesla MRI for every subject. Compared with controls, the
mean LGN heights in glaucoma were decreased in right
(4.09 (0.89) mm vs 4.74 (0.54) mm, p.0.05) and left
LGNs (3.98 (0.57) mm vs 4.83 (0.95) mm; p=0.033).
The combined right and left LGN height in glaucoma was
significantly decreased compared with controls (8.07
(1.06) mm vs 9.56 (0.86) mm; p=0.005).
Conclusion: In vivo MRI evidence of LGN degeneration in
human glaucoma is consistent with ex vivo primate and
human neuropathological studies. LGN atrophy may be a
relevant biomarker of visual system injury and/or
progression in some glaucoma patients.
Glaucoma is a leading cause of world blindness,
and its pathological hallmark is retinal ganglion cell
(RGC) loss. Current therapies are directed at
lowering intraocular pressure, and this helps to
slow disease progression.
1 Although the RGC cell
body lies within the eye, the large part of its axon
lies outside the eye, forming the optic nerve,
chiasm and optic tract. Ninety per cent of the
RGCs terminate in the lateral geniculate nucleus
(LGN), the major relay station between the retina
and visual cortex.
2 In experimental monkey glau-
coma with optic nerve fibre loss, the LGN under-
goes degenerative changes, including overall LGN
shrinkage and reduced neuron size and numbers.
3–6
These findings provide evidence of trans-synaptic
degeneration in glaucoma, and may be relevant to
understanding disease spread in select patients.
7
Neuroimaging studies of the LGN in the context
of vision loss are rare.
8–11 Anatomical challenges
include its small size and maximal diameter of 4–
6m m
12 and proximity to other adjacent grey-
matter thalamic nuclei. Technical challenges
include optimisation of MR imaging parameters
to consistently identify and discriminate the LGN
from surrounding white- and grey-matter struc-
tures.
13 14
In a post-mortem human glaucoma case with
bilateral visual-field loss, reduced LGN and neuron
size were observed by histomorphometry and ex
vivo MRI, compared with age-matched controls.
15
It is not known whether LGN size in glaucoma is
reduced in vivo compared with normal subjects. In
glaucoma patients with similar bilateral visual-field
loss, we prospectively assessed the LGN size in vivo
by 1.5-Tesla MRI compared with age-matched
controls.
PATIENTS AND METHODS
Subjects
Following institutional research ethics board
approval, informed consent was obtained.
Glaucoma subjects (n=10) were recruited pro-
spectively from the Glaucoma and Nerve
Protection Unit at St Michael’s Hospital,
University of Toronto. Inclusion criteria required
a diagnosis of primary open-angle glaucoma, with
evidence of glaucomatous optic neuropathy and
documented visual-field loss involving both eyes.
Exclusion criteria included a history of non-
glaucomatous ocular disease, or neurological dis-
order.
Ten age-matched control subjects were recruited
mainly from hospital personnel and, after informed
consent, underwent complete eye examination and
visual-field testing. Inclusion criteria included
normal eye exam and visual fields. Subjects with
a history of ocular or neurological disease were
excluded. MRIs of eight control subjects were used
in this study, as one subject did not attend the
scheduled session, and another was discovered to
have a history of previously treated ocular hyper-
tension.
There was no statistically significant difference
in mean age between the glaucoma and control
groups (63.1 (SD 7.7) years vs 58.6 (10.0) years;
p.0.05) (table 1). In the glaucoma group,
Humphrey 24-2 visual field MD ranged from
25.06 dB to 220.43 dB, and there was no statis-
tically significant difference in mean deviation
between OD and OS (212.63 (4.18) dB vs
215.76 (4.30) dB; p.0.05). In the glaucoma group,
the vertical cup/disc ratio ranged from 0.5 to 0.9
and there was no statistically significant difference
in cup/disc ratio between OD and OS (0.79 (0.12)
vs 0.77 (0.15); p.0.05). Compared with the control
group, MDs and cup/disc ratio (table 1) were
significantly different in the glaucoma group for
both eyes (p,0.05).
Magnetic resonance imaging
MRI studies were performed on a 1.5-Tesla MRI
scanner (Philips Intera release 1.11, Eindhoven,
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Preliminary experiments were performed using both inversion
recovery and proton density sequences, and images with proton
density measurement were found to be consistently better at
visualising the LGN.
13 14 Multiple sequences were applied:
sagittal T1 (TR/TE 747/14, TSE factor of 5, slice thickness
4 mm gap 10 mm, 2566256 matrix, default slice order acquisi-
tion, NEX of 3); axial FLAIR (TR/TE 11000/140, slice thickness
6 mm gap 1 mm, 2566256 matrix, TSE Factor of 27, default
slice order acquisition, NEX of 1); coronal proton density (TR/
TE 3000/12, slice thickness 2 mm gapless, 2566256 matrix, TSE
factor of 7, default slice order acquisition, NEX of 5); DWI (TR/
TE 3000/75, slice thickness 6 mm, default slice order acquisi-
tion, NEX of 4). All sequences were fast spin echoes or EPI for
the Diffusion series. Sagittal T1 and axial FLAIR images of the
brain were obtained for optimal spatial orientation and to rule
out any incidental abnormality along the visual pathways. LGN
images were acquired in the coronal plane orthogonal to the
long axis of the brainstem reference line (fig 1A).
All scans were of approximately 30 min duration for each
patient, and performed by the same technician, on two separate
days. Thirty-six LGNs of 18 patients were readily detected on
proton density MR images, giving a bright signal intensity
surrounded by low-signal-intensity white-matter tracts, with
anatomical boundaries that included the lateral recess of the
ambient cistern, the posterior limb of the internal capsule and
the optic radiations. In all subjects each LGN was visible on at
least two consecutive images. For each of the 36 LGNs, the
section with the largest cross-sectional area was selected
independently by each of the three neuroradiologists with
100% agreement. Image analysis was performed by three
neuroradiologists who were masked to the diagnosis and who
were able to access coronal images of the LGN only, without
optic nerves and optic chiasm. MR image data were analysed
using Magicweb software (Siemens AG, Medical Solutions,
Health Services. Version: 17.09.2003, Munich, Germany). LGN
height was obtained by drawing a perpendicular line from the
apex of the convexity to the base of the nucleus by consensus of
three neuroradiologists masked to the diagnosis in one session
(fig 1B). To reflect input from both eyes with no significant
difference in cup/disc ratio or mean deviation between OD and
OS in glaucoma, combined right and left LGN heights were
calculated for each subject. Glaucoma and control groups were
compared using the t test.
Neurohistological measurement of LGN height
After research ethics board approval, post-mortem brain speci-
mens (n=4, mean age 74.4 (9.9) years, ranging from 62 to
85 years) were obtained. The left cerebral hemispheres were
used for neuropathological examination, and neurological
diseases were ruled out. Brain specimens containing the right
LGN were cryoprotected, frozen and serially sectioned (50 mm
thick) with a sliding microtome in the coronal plane perpendi-
cular to the optic tract.
3 Every 15th section was stained with
Nissl. Using the section with the largest cross-sectional area,
LGN height was measured by drawing a line from the apex of
the convexity to the base of the nucleus in a perpendicular
fashion with morphometry software (Neurolucida software,
MicroBrightField, Williston, Vermont) and bright-field micro-
scope (SM51, Olympus, Tokyo) (fig 1C). LGN height measure-
ments from MRI scans were also determined by drawing a line
from the apex of the convexity to the base of the nucleus in a
perpendicular fashion.
Table 1 Details of normal and glaucoma subjects
Age Sex
Mean deviation (dB) Cup/disc ratio
OD OS OD OS
Control
C1 71 M 0.45 0.05 0.5 0.3
C2 68 F 3.13 0.53 0.3 0.3
C3 52 M 1.44 1.17 0.3 0.3
C4 46 F 1.9 1.99 0.2 0.2
C5 54 F 20.44 21.69 0.3 0.3
C6 65 M 1.05 3.07 0.7 0.7
C7 66 F 1.17 0.93 0.5 0.5
C8 47 F 20.96 22 0.7 0.7
Mean 58.6 0.97 0.51 0.44 0.41
SD 10.0 1.30 1.72 0.19 0.20
Glaucoma
G1 66 M 211.07 210.93 0.8 0.6
G2 66 M 217.23 215.97 0.8 0.8
G3 52 F 25.06 217.13 0.8 0.8
G4 65 F 211.83 28 0.7 0.6
G5 60 F 220.43 222.1 0.8 0.8
G6 58 F 210.45 218.88 0.9 0.9
G7 76 F 211.17 217.3 0.8 0.9
G8 52 M 214.52 214.44 0.5 0.5
G9 65 F 210.88 220.02 0.9 0.9
G10 71 F 213.69 212.82 0.9 0.9
Mean 63.1 212.63 215.76 0.79 0.77
SD 7.7 4.18 4.30 0.12 0.15
t Test (p value) NS 0.005 0.005 0.0002 0.0005
OD, right eye; OS, left eye.
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In all control and glaucoma subjects, both LGNs were identified,
and examples are given in fig 2.
In control subjects, right and left LGN heights by 1.5-Tesla
MRI ranged from 3.71 mm to 5.31 mm and from 3.36 mm to
5.74 mm, respectively (table 2). The mean right and left LGN
heights were 4.74 (0.54) mm and 4.83 (0.95) mm, respectively,
and this difference was not statistically different (p.0.05)
(fig 3).
Neurohistological measurements of the LGN in four different
normal post-mortem human brain specimens showed a mean
maximum LGN height of 4.9 (0.83) mm. This value is similar to
in vivo MRI measures of the LGN for normal subjects.
In glaucoma, right and left LGN heights by 1.5-Tesla MRI
ranged from 3.08 mm to 5.45 mm and from 3.13 mm to
4.92 mm, respectively (table 2). The mean right and left LGN
heights were 4.09 (0.89) mm and 3.98 (0.57) mm, respectively,
and this difference was not statistically different (p.0.05).
The mean right LGN height in glaucoma was decreased
compared with that observed in controls, but this difference did
not reach statistical significance (4.09 (0.89) mm vs 4.74
(0.54) mm, p.0.05) (fig 3). Fifty per cent of glaucoma subjects
were below the lower 95% confidence limit of the control group
(table 2).
The mean left LGN height in glaucoma was decreased
compared with that observed in controls, and this difference
was statistically significant (3.98 (0.57) mm vs 4.83 (0.95) mm;
p=0.033) (fig 3). Sixty per cent of glaucoma subjects were
below the lower 95% confidence limit of the control group
(table 2).
The combined LGN height (right+left) was calculated to
account for input from each glaucomatous eye to both LGNs.
The combined LGN height in normal and glaucoma subjects
ranged from 8.25 mm to 10.45 mm and from 6.21 mm to
9.26 mm, respectively. Compared with the glaucoma group, the
mean combined LGN height was decreased, and this difference
was statistically significant (8.07 (1.06) mm vs 9.56 (0.86) mm;
p=0.005) (fig 3). Seventy per cent of glaucoma subjects were
below the lower 95% confidence limit of the control group
(table 2).
DISCUSSION
Compared with other elements along the visual axis, neuroima-
ging data relating to the intrinsic structure of the LGN are
scarce, mainly due to its location and small size. Previous studies
Table 2 Right, left and combined lateral geniculate nucleus (LGN)
heights for glaucoma and control patients
Right LGN
height (mm)
Left LGN height
(mm)
Combined LGN
height (mm)
Control
C1 4.89 3.36* 8.25*
C2 5.23 5.07 10.3
C3 3.71* 5.74 9.45
C4 4.83 5.49 10.32
C5 5.03 5.42 10.45
C6 4.21* 4.67 8.88
C7 4.68 5.46 10.14
C8 5.31 3.4* 8.71*
Mean 4.74 4.83 9.56
SD 0.54 0.95 0.86
95% lower
confidence limit
4.29 4.03 8.84
Glaucoma
G1 3.35* 3.7* 7.05*
G2 4.32 4.92 9.24
G3 3.18* 4.69 7.87*
G4 3.08* 3.13* 6.21*
G5 3.46* 3.82* 7.28*
G6 3.47* 3.97* 7.44*
G7 4.49 4.14 8.63*
G8 5.24 3.79* 9.03
G9 5.45 3.28* 8.73*
G10 4.87 4.39 9.26
Mean 4.09 3.98 8.07
SD 0.89 0.57 1.06
t Test (p value) 0.09 0.033 0.005
*LGN height is below the 95% lower confidence limit of the control group.
Figure 1 (A) Sagittal T1 image showing the slice orientation for coronal
scans parallel to the brainstem reference line. (B) Coronal 2 mm proton
density weighted LGN image showing orientation used for height
measurement (white oblique lines). (C) Nissl stained coronal LGN section
showing orientation used for height measurement (black line).
Surrounding anatomical structures are indicated as IC (posterior limb of
internal capsule) and AC (ambient cistern). The calibration bar indicates
1 mm.
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recognise the LGN on only one axial image, with obscuration of
the medial border by the medial geniculate nucleus.
13 14 By using
the coronal plane,
16 in combination with 2 mm thick slices, the
LGN was visible on at least two and sometimes three scans in
our study. The improved visualisation described in this article
may be relevant to detailed assessment of LGN pathology in
various diseases.
17–19 The LGN height measured by MRI in
normal subjects was similar to histomorphometric measure-
ments of the LGN obtained from normal post-mortem brain
specimens. This suggests that LGN height, readily measured by
MRI, might be a tool to assess LGN size in health and disease.
There is evidence that the LGN undergoes degenerative
changes in experimental primate
3–6 and human
15 glaucoma. At
the macroscopic level, there is obvious atrophy of the LGN.
31 5
Histomorphometric measurements indicate neuron shrinkage
and death affecting magno- and parvocellular LGN neurons.
3–6
Thus, findings in this in vivo neuroimaging study of glaucoma
patients with moderate visual-field loss demonstrating LGN
atrophy are in keeping with histological studies showing
reduced size and neural degeneration in experimental and
human glaucoma.
Seven out of 10 glaucoma patients and two of eight control
patients showed a combined LGN height below the lower 95%
confidence limit of the control group. This suggests that at the
present time, this measurement cannot be used for diagnosis of
glaucoma or to assess neural degeneration of the LGN in
glaucoma for an individual patient in cross-sectional studies.
Larger studies are needed to determine LGN variation in normal
populations with gender and age considerations, and to further
understand the contribution of LGN pathology to vision loss in
glaucoma. Since, in this study, all glaucoma patients had
moderate to advanced vision loss, it is not possible to correlate
LGN heights with disease severity. Longitudinal studies are
required to determine whether LGN height reduces with disease
progression. This structural MRI study in glaucoma may also be
relevant toward the application of functional MRI studies of the
LGN in normal and disease states that affect visual path-
ways.
14 20 Reduced LGN size in glaucoma using readily available
1.5-Tesla MRI provides in vivo evidence of LGN atrophy in
glaucoma patients with moderate visual-field loss.
Neurodegenerative diseases such as Alzheimer disease are
associated with progressive cerebral atrophy, and this can be
assessed by MRI.
21 In vivo MRI linear measures including the
Figure 2 Representative coronal proton
density weighted lateral geniculate
nucleus (LGN) images in control #C3 (A)
and glaucoma subjects with lowest (B,
#G1) average (C, #G6) and highest (D,
#G2) LGN heights. The arrows indicate
right and left LGNs. Calibration bar
indicates 50 mm with 10 mm intervals.
Figure 3 Box plots of right, left and
combined lateral geniculate nuclei (LGN)
in A, B and C, respectively. The box
extends from the 25th percentile to the
75th percentile, with horizontal solid and
dotted lines at the median and mean,
respectively. The bars indicate the highest
and lowest values.
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Alzheimer disease assessment.
22 23 Neuroimaging research in
Alzheimer disease also involves longitudinal MRI studies to
track disease progression and exploits MRI to better classify and
stage disease.
21 Further neuroimaging studies of LGN atrophy in
glaucoma may provide new insights into sites of injury and
progressive disease, with LGN atrophy as a potential biomarker
in some cases of moderate to severe glaucoma.
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